Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases

Jagadeesh Bayry; Srini V Kaveri

doi:10.1016/j.tips.2018.08.004

Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases

Trends Pharmacol Sci. 2018 Nov;39(11):919-922. doi: 10.1016/j.tips.2018.08.004. Epub 2018 Sep 7.

Authors

Jagadeesh Bayry¹, Srini V Kaveri²

Affiliations

¹ Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, Paris, F-75006, France. Electronic address: jagadeesh.bayry@crc.jussieu.fr.
² Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, Paris, F-75006, France.

PMID: 30201270
DOI: 10.1016/j.tips.2018.08.004

Abstract

Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases. Among them, the high-affinity FcRn-binding engineered Fc molecule efgartigimod has recently completed phase I clinical trial.

Keywords: Abdegs; Fc-domain; Seldegs; autoimmunity; circulating normal IgG; intravenous immunoglobulin.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Autoimmune Diseases / therapy*
Histocompatibility Antigens Class I / immunology*
Humans
Immunoglobulin G / immunology*
Immunotherapy*
Receptors, Fc / immunology*

Substances

Histocompatibility Antigens Class I
Immunoglobulin G
Receptors, Fc
Fc receptor, neonatal